What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Placebo administered SC on D1 and W12; 300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from W24 to W48.”In the company’s words, NCT07402213 on ClinicalTrials.gov
- Tested for
- Chronic Spontaneous Urticaria (2 trials), Perennial Allergic Rhinitis, Allergic Diseases
- Main trialPhase 3
- “This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.”In the company’s words, NCT07402213 on ClinicalTrials.gov
Other drugs for Chronic Spontaneous Urticaria
- RemibrutinibNovartis · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- LP-003Longbio Pharma · Phase 3
- BarzolvolimabCelldex Therapeutics · Phase 3
- ICP-332Beijing InnoCare Pharma Tech Co., Ltd. · Phase 2/3
Coming up3
- 7 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 7 Jun 2027 | Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. | |
| Phase 2Recruiting | 15 Jul 2026 | Trial of JYB1904 in Chronic Spontaneous Urticaria. | |
| Phase 2Not yet recruiting | Oct 2027 | Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis | |
| Phase 1Not yet recruiting | 30 Jul 2027 | Trial of JYB1904 Injection in Adolescent Participants | |
| Phase 2Completed | 20 Nov 2025 | Trial of JYB1904 in Patients With Allergic Asthma | |
| Phase 1Completed | 10 Jan 2023 | Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026